



## RECURRENT EPISODE OF PRIAPISM DUE TO QUETIAPINE IN A BIPOLAR PATIENT: A CASE REPORT

Abhishek Vadher<sup>\*1</sup>, Kimmyben Patel<sup>2</sup>, Harsh Chapadia<sup>3</sup>, Chunilal Chapadia<sup>4</sup> and Rahul Chauhan<sup>5</sup>

<sup>1</sup>Observer, Griffin Memorial Hospital, Oklahoma.

<sup>2</sup>Observer, North Penn Cardiovascular Institute.

<sup>3</sup>Intern, Medical College, Baroda.

<sup>4</sup>Physician, Chapadia Medical Center.

<sup>5</sup>Observer, Miller School of Medicine, Miami.

**\* Corresponding Author: Dr. Abhishek Vadher**

Observer, Griffin Memorial Hospital, Oklahoma.

Article Received on 29/03/2016

Article Revised on 20/04/2016

Article Accepted on 10/05/2016

### INTRODUCTION

Priapism is a rare side effect of anti-psychotics. Both typical and atypical anti-psychotics can cause priapism. Priapism means persistent and most of the times painful penile erection not associated with sexual stimulation. Priapism can cause urinary retention, cavernosa fibrosis, gangrene and even impotency if it is not treated properly in time. About 50% of priapism patients end up having impotency.<sup>[1]</sup> Drugs account for 25-40% of priapism.<sup>[2]</sup> The most common drugs causing priapism are anti-hypertensives and anti-psychotics.<sup>[1]</sup>

In anti-psychotics, second generation anti-psychotics are more associated with priapism. But the information in the literature is limited. Most common anti-psychotics causing priapism are Risperidone, Olanzapine and Quetiapine. We are reporting a case of recurrent episode of priapism due to Quetiapine use.

### CASE REPORT

A 37 year old male presented to the emergency department with depression with suicidal ideation. The patient was feeling depressed since last 6 months and he had ideas of killing himself since 1 week. Recent stressful conditions in his life was losing his job. On obtaining further history, the patient was found to have a past psychiatric condition of Bipolar disorder type 1. This was diagnosed 12 years back. He had been started on Quetiapine 100 mg BID and then the dose was increased to 400 mg BID. After a week or so, the patient reported an episode of priapism. Patient reported that he went to the emergency and then he was given a medicine by iv route, the name of which the patient cannot recall. He said that the medication worked fine for him and then he was discharged from the emergency department. He was then continued on Quetiapine 200 mg BID for a while and then it was increased to 300 mg BID. He was on the same dose of 300 mg BID for almost 11 years. He was compliant with the medication. But then he relapsed and stopped taking the medication since one year. Patient reported that initially he felt okay without the medication, but then after 6-7 months he started to feel depressed. In this admission, the patient was admitted to the hospital and kept into 1:1 observation. He was started on Quetiapine 100 mg QHS and then increased to 300 mg QHS. On the fifth day of admission, the patient reported to have painful penile erection for 4 hours.

Physical examination showed uncircumscribed fully erect penis with mild tenderness on palpation throughout the penis. Testicular examination was normal. Rest of physical examination was normal. Complete blood count, blood electrolytes and renal and hepatic function tests were normal. Genotype testing was done for cytochrome P450 3A4.<sup>[4]</sup> There was no enzymatic abnormality. The patient was given oral fluids followed by oral Acetaminophen. Then he was given oral Phenylephrine. The patient failed to respond to Phenylephrine. He was then taken to the emergency room. Urology consult was done. He was started on iv fluids and iv Acetaminophen. Then local Lidocaine injection was given to the patient. Blood was withdrawn from the corporal bodies. Eventually the pain of the patient reduced and then there was gradual detumescence.

### COMMENTS

The two theories on the cause of priapism are alpha 1 receptors blockage and genetic abnormalities.<sup>[3]</sup> In genetic abnormalities, cytochrome p450 abnormality is considered to be responsible. Likewise, as per the other hypothesis, alpha 1 blockage and the decreased venous blood outflow from the penis results in priapism. The potential of the occurrence of priapism depends on the affinity of the anti-psychotic to bind the alpha 1 receptors. Risperidone has the maximum affinity of binding to the alpha 1 receptors followed by Quetiapine

followed by Olanzapine. As per the study in 2010<sup>[2]</sup>, the number of reported cases of priapism were 23, 14 and 6 for Risperidone, Olanzapine and Quetiapine respectively. The dispute in the Olanzapine and the Quetiapine reported cases and the scientifically proven affinity of the two drugs for alpha-1 receptors may be due to the issues of length and the use of the drugs in the market or due to lack of reporting of the cases of priapism of Quetiapine.

Dose and the duration of treatment is not related with the occurrence of priapism.<sup>[1]</sup> But as per this case report, we can assume that the sudden rise of drug level in the body causes priapism because priapism was seen in this patient only when Quetiapine was first introduced to the patient and then introduced to the patient after a period of one year. But when the patient was on Quetiapine on a maintenance dose for a long time, it did not cause priapism.

#### REFERENCE

1. Thompson JW, Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. *J Clin Psychiatry.*, 1990; 51(10): 430–433.
2. Penaskovic, Kenan M., Fasiha Haq, and Shakeel Raza. “Priapism During Treatment With Olanzapine, Quetiapine, and Risperidone in a Patient With Schizophrenia: A Case Report.” *Primary Care Companion to The Journal of Clinical Psychiatry* 12.5 (2010): PCC.09100939. PMC. Web. 29 Mar. 2016.
3. Jackson JC, Torrence CL. Quetiapine-induced Priapism Requiring Frequent Emergency Admissions: A Case Report. *Urology Case Reports.*, 2015; 3(1): 1-2. doi:10.1016/j.eucr.2014.09.003.
4. M.J. Geraci, S.L. McCoy, P.M. Crum, et al. Anti-psychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction *Int J Emerg Med*, 2010; 3: 81–84.